Loteprednol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Allergic and inflammatory conditions of the eye As 0.5% susp: Instill 1-2 drops 4 times/day. Seasonal allergic conjunctivitis As 0.2% susp: Instill 1 drop 4 times/day. Post-op ocular inflammation As 0.5% susp: Instill 1-2 drops 4 times/day, beginning 24 hr after surgery and continuing through the 1st 14 days of post-op period. As 0.5% oint: Apply approx 1/2 inch ribbon 4 times/day, beginning 24 hr after surgery and continuing through the 1st 14 days of post-op period. As 0.5% gel: Instill 1-2 drops 4 times/day, beginning 24 hr after surgery and continuing through the 1st 14 days of post-op period
Dosage Details
Ophthalmic
Postoperative ocular inflammation
Adult: As 0.5% susp: Instill 1-2 drops onto affected eye(s) 4 times daily, beginning 24 hr after surgery and continuing through the 1st 14 days of post-op period. As 0.5% oint: Apply approx 1/2 inch ribbon into the conjunctival sac onto the affected eye(s) 4 times daily, beginning 24 hr after surgery and continuing through the 1st 14 days of post-op period. As 0.5% gel: Instill 1-2 drops to the affected eye(s) 4 times daily, beginning 24 hr after surgery and continuing through the 1st 14 days of post-op period.

Ophthalmic
Seasonal allergic conjunctivitis
Adult: As 0.2% susp: Instill 1 drop onto affected eye(s) 4 times daily.

Ophthalmic
Allergic and inflammatory conditions of the eye
Adult: As 0.5% susp: Instill 1-2 drops onto affected eye(s) 4 times daily.
Contraindications
Ocular viral (e.g epithelial herpes simplex keratitis), fungal, and mycobacterial infection.
Special Precautions
Patient w/ glaucoma, history of ocular herpes simplex. Pregnancy and lactation.
Adverse Reactions
Significant: Increased ocular pressure, optic nerve injury, visual acuity and field of vision defect, posterior subcapsular cataract formation, corneal or scleral thinning, delayed wound healing, secondary ocular infection (e.g. bacterial, viral, fungal infection).
Nervous: Headache.
Resp: Pharyngitis, rhinitis.
Ophthalmologic: Application site burning, foreign body sensation, chemosis, anterior chamber inflammation, blurred vision, epiphora, eye discharge, photophobia, visual disturbance, xerophthalmia, conjunctival hyperaemia, corneal oedema, eye pain, blepharitis, conjunctivitis, corneal changes, eye irritation, keratoconjunctivitis, uveitis, conjunctival papillae.
Dermatologic: Pruritus.
Patient Counseling Information
Remove contact lenses prior to ophth admin and reinsert after 15 min. This drug may cause transient effects on vision, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor intraocular pressure (if used for >10 days); signs and symptoms of other infections (e.g. fungal).
Drug Interactions
May increase the risk of intraocular pressure w/ cycloplegics and other ocular hypotensive agents.
Action
Description: Loteprednol is a corticosteroid w/ a glucocorticoid activity. It is highly lipid soluble which enhances cell penetration to induce the production of lipocortin protein that modulates the activity of prostaglandin and leukotrienes resulting in the inhibition of inflammatory response.
Onset: W/in 2 hr.
Pharmacokinetics:
Metabolism: Undergoes extensive metabolism into inactive carboxylic acid metabolite.
Chemical Structure

Chemical Structure Image
Loteprednol

Source: National Center for Biotechnology Information. PubChem Database. Loteprednol, CID=9865442, https://pubchem.ncbi.nlm.nih.gov/compound/Loteprednol (accessed on Jan. 22, 2020)

Storage
Store at 15-25°C. Do not freeze.
MIMS Class
ATC Classification
S01BA14 - loteprednol ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
References
Alrex Suspension Drops (Bausch & Lomd Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/07/2017.

Anon. Loteprednol Etabonate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/07/2017.

Anon. Loteprednol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/07/2017.

Buckingham R (ed). Loteprednol Etabonate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/07/2017.

Joint Formulary Committee. Loteprednol Etabonate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/07/2017.

Lotemax Gel (Bausch & Lomd Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/07/2017.

Lotemax Ointment (Bausch & Lomd Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/07/2017.

Lotemax Suspension/Drops (Bausch & Lomd Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/07/2017.

Disclaimer: This information is independently developed by MIMS based on Loteprednol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in